
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The OsteoCool™ Post-Market Clinical Study (OPuS One) is a multicenter study collecting real-world evidence on the efficacy and safety of OsteoCool™. Twelve-month data show outcomes in 206 patients treated with OsteoCool™, as well as pain relief and improved quality of life in as soon as three days1.
The OsteoCool RF ablation system is cooled radiofrequency ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumors, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.
Intro to OsteoCool™ RF Ablation System Animation
More information (see more)
Less information (see less)
INDICATIONS
RISKS
Levy J, David E, Hopkins T, et al. Improvement in Quality of Life on Patients Treated for Painful Osseous Metastases With Radiofrequency Ablation: The Opus One Study, abstract presented at Society for Interventional Radiology Annual Scientific Meeting, March 20-26, 2021, virtual. https://www.researchgate.net/publication/351170997_Abstract_No_78_Improvement_in_quality_of_life_in_patients_treated_for_painful_osseous_metastases_with_radiofrequency_ablation_the_OPuS_One_study. Accessed November 8, 2021.